Literature DB >> 7677996

Multiple activation states of VLA-4. Mechanistic differences between adhesion to CS1/fibronectin and to vascular cell adhesion molecule-1.

A Masumoto1, M E Hemler.   

Abstract

We examined the effects of a stimulatory anti-beta 1 mAb (TS2/16) and different divalent cations on VLA-4-mediated cell adhesion to vascular cell adhesion molecule-1 (VCAM-1), to the fibronectin-derived CS1 peptide, and to larger fibronectin fragments. Using optimal binding conditions (in the presence of mAb TS2/16 and 1.0 mM Mn2+), the levels of VLA-4-mediated adhesion to VCAM-1 and to CS1 peptide were virtually indistinguishable, and half-maximal inhibition of adhesion to both ligands was achieved using similar levels of an anti-alpha 4 antibody. However, using suboptimal adhesion conditions, two critical differences between adhesion to CS1 peptide (or larger fibronectin fragments) and VCAM-1 were consistently observed. First, stimulation by added mAb TS2/16 had a substantially greater effect on adhesion to CS1 than to VCAM-1 and second, Ca2+ was much less able to support adhesion to CS1 than to VCAM-1. These two differences between adhesion to CS1 peptide and to VCAM-1 were most obvious among cell lines which synthesized inactive or partly active VLA-4 but were not obvious for fully active VLA-4. Together, these results not only reveal crucial differences in the mechanisms of VLA-4 binding to its two ligands, but also lead to increased understanding of the variable activation states of VLA-4. The differential ability to utilize Ca2+ displayed by VLA-4 in different states of activation and the activation of inactive or partly active VLA-4 by the addition of Mn2+ both point to divalent cation sites playing an essential role in determining VLA-4 regulation and ligand specificity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7677996

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  Integrins alpha2beta1 and alpha4beta1 can mediate SA11 rotavirus attachment and entry into cells.

Authors:  M J Hewish; Y Takada; B S Coulson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  A novel region of the alpha4 integrin subunit with a modulatory role in VLA-4-mediated cell adhesion to fibronectin.

Authors:  M Muñoz; J Serrador; M Nieto; A Luque; F Sánchez-Madrid; J Teixidó
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

Review 3.  Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.

Authors:  M P Rettig; G Ansstas; J F DiPersio
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

4.  The integrin VLA-4 supports tethering and rolling in flow on VCAM-1.

Authors:  R Alon; P D Kassner; M W Carr; E B Finger; M E Hemler; T A Springer
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

Review 5.  The pathophysiologic role of alpha 4 integrins in vivo.

Authors:  R R Lobb; M E Hemler
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 6.  Adhesion molecules in rheumatoid arthritis.

Authors:  N Oppenheimer-Marks; P E Lipsky
Journal:  Springer Semin Immunopathol       Date:  1998

7.  Integrin alpha5beta1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16.

Authors:  E Davison; R M Diaz; I R Hart; G Santis; J F Marshall
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 8.  Pathophysiological aspects of VLA-4 interactions and possibilities for therapeutical interventions.

Authors:  T W Kuijpers
Journal:  Springer Semin Immunopathol       Date:  1995

9.  Differential regulation of beta 1 and beta 2 integrin avidity by chemoattractants in eosinophils.

Authors:  C Weber; J Kitayama; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

10.  Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.

Authors:  Deepti Soodgupta; Haiying Zhou; Wissam Beaino; Lan Lu; Michael Rettig; Mark Snee; James Skeath; John F DiPersio; Walter J Akers; Richard Laforest; Carolyn J Anderson; Michael H Tomasson; Monica Shokeen
Journal:  J Nucl Med       Date:  2016-01-07       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.